RWA
CRSP icon

Ropes Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Ropes Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,130
Closed -$173K – 368
2020
Q4 		$173K Buy
1,130
+1,000
+769% +$118K 0.03% 241
2020
Q3 		$11K Hold
130
– – ﹤0.01% 502
2020
Q2 		$10K Hold
130
– – ﹤0.01% 443
2020
Q1 		$6K Hold
130
– – ﹤0.01% 444
2019
Q4 		$8K Hold
130
– – ﹤0.01% 477
2019
Q3 		$5K Hold
130
– – ﹤0.01% 510
2019
Q2 		$6K Hold
130
– – ﹤0.01% 508
2019
Q1 		$5K Buy
+130
New +$4.5K ﹤0.01% 483

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ropes Wealth Advisors's CRSP Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 1,130 shares — an estimated $173K sold.

Ropes Wealth Advisors first reported a position in CRSP in Q1 2019 and held it in 8 quarters. The position peaked at $173K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Ropes Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Ropes Wealth Advisors sold 1,130 CRISPR Therapeutics shares in Q1 2021, an estimated $173K.
  • Ropes Wealth Advisors first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 8 quarters.
  • Ropes Wealth Advisors's CRISPR Therapeutics position peaked at $173K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.